Emmessar Biotech & Nutrition Limited (BOM:524768)
India flag India · Delayed Price · Currency is INR
25.99
-0.21 (-0.80%)
At close: May 26, 2026

BOM:524768 Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Revenue
3.716.115.5510.193.65
Other Revenue
20.3615.2414.8614.9614.08
24.0721.3520.4225.1517.73
Revenue Growth (YoY)
12.75%4.55%-18.82%41.83%-79.03%
Cost of Revenue
0.881.8524.341.35
Gross Profit
23.1919.4918.4220.8116.38
Selling, General & Admin
10.799.7510.068.718.02
Other Operating Expenses
5.584.034.153.862.57
Operating Expenses
17.3714.7615.1813.511.52
Operating Income
5.824.743.247.314.86
Interest Expense
-0.03-0.01---
Interest & Investment Income
-4.834.92.412.09
Currency Exchange Gain (Loss)
-0.01-0.02-0.05-0.09
Other Non Operating Income (Expenses)
---0--
EBT Excluding Unusual Items
5.89.588.129.676.87
Gain (Loss) on Sale of Investments
-0.010.010-
Pretax Income
5.89.588.139.679.32
Income Tax Expense
1.446.420.634.634.56
Net Income
4.363.167.55.044.75
Net Income to Common
4.363.167.55.044.75
Net Income Growth
37.86%-57.82%48.79%5.97%-67.21%
Shares Outstanding (Basic)
55555
Shares Outstanding (Diluted)
55555
Shares Change (YoY)
7.72%----0.00%
EPS (Basic)
0.810.631.501.010.95
EPS (Diluted)
0.810.611.481.010.95
EPS Growth
32.79%-58.78%46.77%5.97%-67.21%
Free Cash Flow
2.572.246.453.519.64
Free Cash Flow Per Share
0.480.451.290.703.93
Gross Margin
96.35%91.32%90.21%82.75%92.38%
Operating Margin
24.19%22.19%15.87%29.07%27.43%
Profit Margin
18.11%14.81%36.72%20.03%26.81%
Free Cash Flow Margin
10.66%10.48%31.57%13.91%110.78%
EBITDA
6.825.714.228.255.79
EBITDA Margin
28.35%26.77%20.64%32.79%32.64%
D&A For EBITDA
10.980.980.940.92
EBIT
5.824.743.247.314.86
EBIT Margin
24.19%22.19%15.87%29.07%27.43%
Effective Tax Rate
24.79%67.00%7.75%47.89%48.96%
Revenue as Reported
24.0726.225.4727.722.84
Advertising Expenses
-0.230.220.170.17
Source: S&P Global Market Intelligence. Standard template. Financial Sources.